Madrigal Pharmaceuticals Inc(MDGL) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials for the treatment of NASH and hyperlipidemia. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

Current Price

$126.71

RSI

36.620

Beta:

1.074131

February 25, 2021
54M
786K
-55M

-113.133 %
-65.435 %

$0
$0
$0
$0
$0
$0
0.000 %
0.000 %
0.000 %
0.000 %
0.000 %

$-202,244,000
$-83,948,000
$-32,811,000
$-31,154,000
$-26,387,858
$-68,671,000
-58.492 %
-60.915 %
-5.050 %
-15.299 %
160.237 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.